AusBiotech

AusBiotech and MTPConnect were thrilled to co-host a reception at the Australian Parliament House, welcoming delegates from the National Biotech and Medtech Development and Commercialisation Policy Summit.

CLINUVEL (ASX:SUV) says it is in late-stage discussions with the European Medicines Agency to increase the recommended maximum number of doses per year of its drug SCENESSE (afamelanotide) for adult patients with erythropoietic protoporphyria.

AI-driven clinical trial design and optimisation company Opyl (ASX: OPL) has signed a service-level agreement with Southern Clinical Development Consulting.

Race Oncology (ASX:RAC) says it has completed an FTO-targeted drug discovery program at Monash University’s Fragment Platform.

BioMelbourne Network is launching a one-year project to develop a central portal containing a workforce resource suite, thanks to the Victorian Government's support.

Melbourne-based company Neurizon Therapeutics has announced positive results from a preclinical study of its lead candidate, NUZ-001.

Today’s National Biotech and Medtech Development and Commercialisation Summit 2024 in Canberra will bring together more than 100 of Australia’s leading industry figures, policy experts, and innovators with the aim of shaping the future of the nation’s biotech and medtech sectors.

Australian company AdAlta (ASX:1AD) has announced the appointment of two new directors, including experienced industry executives Michelle Burke and Iain Ross.

Clinical-stage nuclear medicine company Radiopharm Theranostics (ASX:RAD) has announced the publication of positive results of a retrospective study of the biokinetics of 68Ga-RAD 301 in pancreatic cancer patients.

Australian company CLINUVEL has announced several changes to prioritise its resources towards three critical areas of clinical development.

Clinical-stage company Immutep (ASX:IMM) has announced positive data from the investigator-initiated INSIGHT-003 Phase 1 trial evaluating its eftilagimod alpha in combination with MSD's KEYTRUDA (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer.

Amplia Therapeutics (ASX:ATX) has announced that it has entered into a research collaboration with Korean preclinical drug screening company Next&Bio.